Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/01.mao.0000247813.78206.8a | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
FDFT1 maintains glioblastoma stem cells through activation of the Akt pathway.
Stem Cell Res Ther
December 2024
Department of Pathology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, 33 Ying Feng Road, Guangzhou, 510120, China.
Background: Cancer stem cells (CSCs) have unique metabolic characteristics and are hypothesized to contribute significantly to the recurrence and drug resistance of glioblastoma multiforme (GBM). However, the reliance on mitochondrial metabolism and the underlying mechanism of glioblastoma stem cells (GSCs) remains to be elucidated.
Methods: To quantify differential mitochondrial protein expression between GSCs and differentiated cells, a mass spectrum screen was applied by the Stable Isotope Labeling with Amino Acids in Cell Culture (SILAC) technique.
Virus-Inspired Biodegradable Tetrasulfide-Bridged Mesoporous Organosilica with GSH Depletion for Fluorescence Imaging-Guided Sonodynamic Chemotherapy of Glioblastoma Multiforme.
ACS Appl Mater Interfaces
December 2024
Department of Neurosurgery, Zhongshan Hospital of Xiamen University, Xiamen University, School of Medicine, Xiamen, Fujian 361004, China.
Glioblastoma multiforme (GBM), a highly prevalent and lethal form of malignant tumor, is typically treated with Temozolomide (TMZ), a chemotherapeutic agent. Nevertheless, the effectiveness of TMZ is hampered by inadequate cell entry, systemic adverse effects, and monotherapy constraints. Previous clinical studies have demonstrated that combination therapy can significantly enhance the therapeutic efficacy.
View Article and Find Full Text PDFClinical research framework proposal for ketogenic metabolic therapy in glioblastoma.
BMC Med
December 2024
Biology Department, Boston College, Chestnut Hill, MA, 02467, USA.
Article Synopsis
- Glioblastoma (GBM) is the deadliest brain tumor in adults, and current therapies are largely ineffective, which drives the need for new treatment strategies based on the tumor's metabolic needs, specifically glucose and glutamine.
- A ketogenic metabolic therapy (KMT) approach targets these metabolic pathways by combining dietary changes with specific drugs to limit glycolysis and glutaminolysis, while promoting the use of non-fermentable fuels like ketones and fatty acids.
- The glucose-ketone index (GKI) serves as a biomarker to monitor treatment effectiveness, aiming to create a more hostile environment for tumor growth and improve outcomes in GBM as well as potentially other cancer types reliant on similar metabolic pathways.
A Case of Anterior Cingulotomy for Intractable Pain Caused Thalamic Glioma.
J Korean Neurosurg Soc
December 2024
Department of Functional Neurosurgery and Neuromodulation, Romodanov Neurosurgery Institute, Kyiv, Ukraine.
Article Synopsis
- Stereotactic bilateral anterior cingulotomy is a surgical method used to treat thalamic pain syndrome, specifically targeting lesions in the anterior and midcingulate cortex.
- A case study of a 45-year-old man with a right thalamus lesion causing severe pain showed that combining cingulotomy with a biopsy led to complete pain relief shortly after the procedure.
- The biopsy revealed a diffuse astrocytoma, and although pain was managed for 4 years post-surgery, it returned due to tumor growth, illustrating that this dual approach can effectively alleviate pain while also identifying the lesion's nature for further treatment.
Novel tri-specific T-cell engager targeting IL-13Rα2 and EGFRvIII provides long-term survival in heterogeneous GBM challenge and promotes antitumor cytotoxicity with patient immune cells.
J Immunother Cancer
December 2024
Vaccine and Immunotherapy Center, Wistar Institute, Philadelphia, Pennsylvania, USA
Article Synopsis
- Glioblastoma multiforme (GBM) presents a challenge for treatment due to its antigenic variability, prompting researchers to develop multivalent immunotherapies that target multiple tumor antigens to improve effectiveness.
- The study introduces a new class of antibodies called DNA-encoded tri-specific T-cell engagers (DTriTEs) that target two specific GBM antigens and engage T cells, showing promising in vitro and in vivo results.
- The leading DTriTE construct, DT2035, not only significantly reduced tumor burden and improved survival rates in mouse models but also showed sustained expression and induced strong immune responses, making it a potential game-changer for GBM treatment.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!